NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Pharming Group N.V. (PHAR) Stock Analysis

Pharming Group N.V. (PHAR) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

PHAR

$11.23

−$0.23 (−2.01%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PHAR with… →

PHAR Key Statistics

As of Sep 4, 2026
Trading
Open
$11.16
Previous Close
$11.46
Day's Range
11.16–11.54
52-Week Range
9.62–21.34
Volume
5.50K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.07
Valuation
Market Cap
$794.84M
P/E Ratio
80.21
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
36.58
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.17
EPS (ttm)Profit attributable to each share over the last twelve months.
0.14
Financials (FY)
Revenue (FY)
$376.13M+26.56%
Net Income (FY)
$2.85M
Profit marginThe share of revenue left as profit after all costs and taxes.
2.54%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
70.78M
1-Year Return
−24.48%
Dividend and dates
Avg Volume
13.31K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

PHAR Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−36.45%
2025+75.56%
2024−11.94%
2023+3.63%
2022+23.38%
2021−41.16%
2020 (partial year)−9.01%

As of September 4, 2026.

PHAR Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$376.13M$2.85M0.8%
2024$297.20M−$11.84M−4.0%
2023$245.32M−$10.55M−4.3%
2022$205.62M$13.67M6.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$376.13M$330.63M$20.88M$2.85M0.8%
2024$297.20M$261.80M−$3.67M−$11.84M−4.0%
2023$245.32M$220.10M−$22.29M−$10.55M−4.3%
2022$205.62M$188.06M$9.86M$13.67M6.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

PHAR Valuation vs Biotechnology Median

Median of 656 stocks
MetricPHARBiotechnology medianvs median
P/E80.2112.576.4x the median
P/S ratio2.1715.260.1x the median
Profit margin2.54%0.00%2.5 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 8 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Pharming Group N.V. (PHAR) is capitalised at $794.84M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 407.

Over the past 52 weeks the price has ranged from $9.62 to $21.34. The most recent close on file for PHAR is $11.23, dated September 4, 2026. That is −$0.23 (−2.01%) against the previous close. The latest close sits 16.74% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $376.13M. Against the prior fiscal year total of $297.20M, that is a change of +26.56%. The same year closed with net income of $2.85M. Profit margin runs at 2.54%. That is 2.5 percentage points above the Biotechnology median of 0%. Trailing earnings per share are 0.14.

Across the 4 fiscal years on file, revenue moves from $205.62M in 2022 to $376.13M in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 80.21. That is 6.4 times the Biotechnology median of 12.57. The forward P/E on file is 36.58. Measured against sales, the shares trade at 2.17 times revenue. On price-to-sales that is 0.1 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 0.07. Annualized volatility over the trailing 5 years is 70.6%. Over the trailing twelve months the price has returned −24.48%. Measured over 5 years, that is +0.32% a year compounded.

Growth & Income

The record shows no dividend for PHAR.

Across the complete calendar years on file, 2025 returned +75.56% and 2021 returned −41.16%. Of the 5 complete calendar years on file, 3 finished higher. 2026 is still running; the price is −36.45% year to date.

Peer Comparison

Pharming Group N.V. (PHAR) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Pharming Group N.V. PHAR $794.84M 80.2
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Pharming Group N.V. trades at a P/E of 80.2.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Pharming Group N.V.

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K? inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Visit website →